HUTCHMED (NASDAQ:HCM) Reaches New 52-Week Low – Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $12.89 and last traded at $12.87, with a volume of 4366 shares trading hands. The stock had previously closed at $13.20.

Analyst Ratings Changes

Separately, StockNews.com downgraded HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Price Performance

The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average is $14.70 and its 200-day moving average is $17.14.

Hedge Funds Weigh In On HUTCHMED

A number of large investors have recently modified their holdings of HCM. Jane Street Group LLC increased its holdings in HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after buying an additional 49,366 shares in the last quarter. State Street Corp increased its stake in HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock valued at $6,826,000 after purchasing an additional 3,078 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock valued at $268,000 after purchasing an additional 1,799 shares in the last quarter. M&G PLC raised its holdings in HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company’s stock worth $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.